Immunostimulating Activity of Beta-Glucan Isolated from the Cell Wall of Mutant Saccharomyces cerevisiae, and Its Anti-Tumor Application in Combination with Cisplatin |
Kim, Wan-Jae
(Dept. of Biotechnology, Konkuk University)
Yoon, Taek-Joon (Dept. of Food & Nutrition, Yuhan University) Kim, Dong-Woo (Natural F&P Co., Ltd) Moon, Won-Kook (Natural F&P Co., Ltd) Lee, Kwang-Ho (Dept. of Biotechnology, Konkuk University) |
1 | Westermann J, Reich G, Kopp J, Haus U, Dorken B, Pezzutto A. 2001 Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother 49:613-620 DOI ScienceOn |
2 | Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, Geertsen P, Straten P. 2003. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13:449-459 DOI ScienceOn |
3 | Kovacs E. 2000. Serum level IL-12 and the production of IFNgamma, IL-2 and IL-4 by peripheral blood mononuclear cell (PBMC) in cancer patients treated with Ciscum albun extract. Biomed Pharmacother 54:305-310 DOI ScienceOn |
4 | Tsang RY, Al-Fayea T, Au HJ. 2009. Cisplatin overdose: toxicities and management. Drug Saf 32:1109-1122 DOI ScienceOn |
5 | Kim DG, Kim Kj, Ju SM, Kim YI, Choi HS, Keum KS, Kim WS, Gao YA, Jeon BH. 2003. Protective effect of Ganopoly and Ganopoly/C+ on nephrotoxicity induced by cisplatin in rat. Korean J Orient Physiol Pathol 17:316-325 과학기술학회마을 |
6 | Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW. 2009. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer in press |
7 | Dauphinee MJ, Kipper SB, Wofsy D, Talal N. 1981. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 127:2483-2487 |
8 | Wang SY, Hsu ML, Hsu HC, Tzeng CH, Lee SS, Shiao MS, Ho CK. 1997. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 70:699-705 DOI ScienceOn |
9 | Carlton BC, Brown BJ, Gene mutation. 1981. Manual of Methods for General Bacteriology. pp.222-242. American Society for Microbiology |
10 | Chan GCF, Chan WK, Sze DMY. 2009. The effect of on human immune and cancer cells. J Hematol Oncol 2:1-11 DOI ScienceOn |
11 | Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. 1991. IL-10 acts on the antigenpresenting cell to inhibit cytokine production by Th1 cells. J Immunol 146:3444-3451 |
12 | Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H, Nakamura M, Ueyama Y. 2000. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 11:815-819 DOI ScienceOn |
13 | Jeong JH, Lee JM, Lee CH, Cho JH, Jang JB, Lee KS. 2009. Anti-tumor metastatic effect and activation of innate immunity by extracy of Mori radicis cortex. J Orient Obstet Gynecol 22:31-40 과학기술학회마을 |
14 | Lin WW, Karin M. 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175-1183 DOI ScienceOn |
15 | Kelly G, Edmund G. 2001. Process for glucan preparation and therapeutic uses of glucan. US Patent 6,242,594 |
16 | Kogan G, Pajtinka M, Babincova M, Miadokova E, Rauko P, Slamenova D, Korolenko TA. 2008. Yeast cell wall polysaccharides as antioxidants and antimutagens: Can they fight cancer? Neoplasma 55:387-393 |
17 | Lasek W, Feleszko W, Golab J, Stokłosa T, Marczak M, Dabrowska A, Malejczyk M, Jakobisiak M. 1997. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 2:100-108 |
18 | Liu J, Gunn L, Hansen R, Yan J. 2009. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp Mol Pathol 86:208-214 DOI ScienceOn |
19 | Masuda Y, Inoue M, Miyata A, Mizuno S, Nanba H. 2009. Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice. Int Immunopharmacol 9:620-626 DOI ScienceOn |
20 | Park JH, Kang MS, Kim HI, Chung BH, Lee KH, Moon WK. 2003. Study on immuno-stimulating activity of isolated from the cell wall of yeast mutant Saccharomyces cerevisiae IS2. Korean J Food Sci Technol 35:483-492 과학기술학회마을 |
21 | Romagnani S. 1991. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 21:152-158 |
22 | Song HS, Moon KY. 2006 In vitro antioxidant activity profiles of isolated from yeast Saccharomayces cerevisiae and mutant Saccharomayces cerevisiae IS2. Food Sci Biotechnol 15:437-440 과학기술학회마을 |
23 | Tohamy AA, El-Ghor AA, El-Nahas SM, Noshy MM. 2003. Beta-glucan inhibits the genotoxicity of cyclophosphamide, adriamycin and cisplatin. Mutat Res 10:45-53 |
24 | Yoon TJ, Kim TJ, Lee H, Shin KS, Yun YP, Moon WK, Kim DW, Lee KH. 2008. Anti-tumor metastatic activity of purified from mutated Saccharomyces cerevisiae. Int immunopharmacol 8:36-42 DOI ScienceOn |
25 | Urosevic M, Dummer R. 2003. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol 13:337-342 DOI ScienceOn |
26 | Yao D, Zhang X, Wei H, Tian Z. 2005. Antisense-induced blockade of GATA-3 expression could inhibit Th2 excursion of tumor cells in vitro and in vivo. Cell Mol Immunol 2:189-196 |